about the product
An almost white opaque, viscous liquid.
Specifications
Name
Modelax®-N
Dosage form
RECTAL SOLUTION
Nosological classification
Laxatives
INN
SODIUM LAURYL SULFOACETATE+SODIUM CITRATE+SORBITOL
Dosages
NOT SPECIFIED
ATC code
A06AG11
Active substance
Sodium citrate dihydrate — 102.6 mg (in terms of sodium citrate) — 90.0 mg
Sodium lauryl sulfoacetate 70% — 12.9 mg (in terms of sodium lauryl sulfoacetate) — 9.0 mg
Sorbitol — 625.0 mg
Pharmacotherapeutic group
General therapy drugs
use
Adults and children over 3 years old
To inject the entire contents of one microclysm (5 ml) rectally, inserting the tip along the entire length (the length of the universal tip is 44.5 mm).
Newborns and children under 3 years of ageTo inject the entire contents of one microclysm (5 ml) rectally, inserting a universal tip by half the length
If the complaints persist for a long time, it is necessary to consult a doctor.For children under 3 years of age, it is also possible to use a microclyster with a shortened tip (the length of the shortened tip is 27 mm. In this case, it is necessary to insert the entire contents of one microclyster with a shortened tip rectally, inserting the tip to its full length.
Instructions for use: Break off the seal on the tip of the tube. Lightly press on the tube so that a drop of the drug lubricates the tip of the enema - this will facilitate the injection process. Insert the tip of the enema into the rectum. Squeeze the tube and squeeze out its contents completely. Remove the tip, still slightly squeezing the tube
Help
Package leaflet
Modelax-N is a combination drug that has a laxative effect. The effect occurs after 5 to 15 minutes. The composition of the drug includes sodium citrate (a peptizer that displaces bound water contained in feces), sodium lauryl sulfoacetate (dilutes intestinal contents) and sorbitol (enhances laxative effect by stimulating the flow of water into the intestine). Increasing the amount of water due to peptization and dilution helps to soften the stool and facilitates bowel movement.
Constipation, including encopresis, preparation for endoscopic (rectoscopy) and X-ray examination of the gastrointestinal tract.
No cases of overdose have been reported with the drug.
According to spontaneous reports of adverse events
Adverse reactions that occur during the use of the drug, which were identified during post-marketing use, were classified as follows: very frequent (10%), frequent (1%, but 10%), infrequent (0.1%, but1%), rare (0.01%, but 0.1%), very rare (0.01%) and adverse reactions with unknown frequency of occurrence (frequency of occurrence cannot be estimated based on available data).
If you experience any adverse reactions listed in the instructions or they worsen, or you notice any other adverse reactions not listed in the instructions, inform your doctor.
Disorders of the gastrointestinal tract.
Very rarely: abdominal pain (including abdominal discomfort, abdominal pain, and upper abdominal pain); discomfort in the anorectal area, loose stools.
Disorders of the immune system.
Very rare: hypersensitivity reactions (e.g. urticaria).Increased individual sensitivity to the components of the drug.
There is a risk of necrosis of the large intestine with simultaneous oral / rectal administration of sodium polystyrene sulfate and sorbitol, which is part of the drug.
Registration certificate holder
JSC Biochemist, Russian Federation
15A Vasenko St., Saransk, Republic of Mordovia, 430030
Manufacturer
JSC Biochemist, Russian Federation
Address: 15A Vasenko str., Saransk, 430030, Republic of Mordovia
Phone number: +7 (8342) 38 03 68
Email: biohimic@promomed.pro
Internet address: promomed.ru
An organization that accepts consumer claims
JSC Biochemist, Russian Federation
Address: 15A Vasenko St., Saransk, 430030, Republic of Mordovia
Phone number: 8 800 222 95 63; 8 800 777 86 04 ( around the clock)
Email: hot_line@promomed.pro
At a temperature not exceeding 25 ° C. Keep out of reach of children.
3 years. Do not use after the expiration date.
They are available without a prescription.
The use of the drug does not affect the ability to perform potentially dangerous activities that require increased concentration of attention and speed of psychomotor reactions (driving vehicles, working with moving mechanisms, the work of a dispatcher, operator).
Adequate and strictly controlled studies involving pregnant women have not been conducted. Since the drug is probably absorbed into the systemic circulation to a small extent, when used in accordance with the recommendations during pregnancy or lactation, undesirable effects for the fetus or infant are not expected.
our partners
Where to buy
